The MUSC Clinical Neuroscience Division (CND) was founded by Dr. Kathleen Brady, a nationally and internationally recognized leader in the substance abuse field. CND faculty work collaboratively to investigate mechanisms, causes, and treatments for a number of psychiatric disorders with emphasis on substance abuse disorders and psychiatric disorders that frequently co-occur with substance abuse.
We are conducting federally funded research on marijuana, cocaine, opiate, alcohol, and nicotine dependence, as well as schizophrenia, bipolar disorder, attention deficit hyperactivity disorder and post-traumatic stress disorder. In all cases, studies involve a multidisciplinary team of investigators using state-of-the-art approaches to better understand the causes of these disorders in order to improve prevention and treatment. Clinical trials of empirically based substance abuse treatments are conducted in front-line treatment settings with the ultimate goal of enhancing communication/collaboration so that clinical practice is increasingly informed by scientific development. Through these initiatives, the CND is helping to improve the translation of basic science findings to clinical practice, and to move best clinical practices into front-line treatment settings.
The CND includes the following programs and centers:
Addition Psychiatry Fellowship Program. This ACGME-accredited fellowship will instruct the PGY-5 psychiatry resident on the prevention, evaluation, and treatment of disorders related to substance abuse, while providing related education and exposure to addictions research. The Addiction Psychiatrist requires knowledge of pharmacology, psychiatry, general medicine, as well as an understanding of how to work effectively and collaboratively with other mental health providers and allied health professionals including nurses, social workers, psychologists, nurse practitioners, counselors, pharmacists, and others who participate in the patient care. Successful completion qualifies the fellow to apply for subspecialty certification in addiction psychiatry from the American Board of Psychiatry and Neurology.
BIRCWH: Building Interdisciplinary Research Careers in Women’s Health. MUSC’s BIRCWH program supports the research career development of junior faculty members who have recently completed clinical training or postdoctoral fellowships, and who have mentorship and a solid plan for training in basic research, translational research, clinical research, and/or health services research relevant to women's health in the areas of mental health, addiction, aging or cognitive decline. BIRCWH is a K12 career development program co-funded by the Office of Research on Women’s Health (ORWH) and the NIHCD. It is one of only 26 such grants in the U.S.
CTN: Southern Consortium Node of the NIDA-funded Clinical Trials Network. This node of the CTN was initiated at MUSC in 2000 as one of only 17 such centers throughout the US designed to focus on bridging the gap between research and treatment in the field of addictions and substance abuse. The CTN is a partnership between academic medical centers and community treatment programs, with the primary mission of translating efficacious treatment methods from academic medical settings to real-life treatment settings. Partners include Duke University and the University of New South Wales in Australia.
DART: Drug Abuse Research Training. The NIDA-sponsored Psychiatry Residency Program at MUSC offers a Research Track for PGY3 and PGY4 residents committed to pursuing research careers. DART’s primary goal is to increase the number of physicians with the skills to conduct patient-oriented research as independently funded investigators, and does so within the same 4-year time period required for clinical training and board certification in psychiatry. In addition, the training format qualifies residents for the very popular NIH Clinical Research Loan Repayment Program.
SCOR: Specialized Center of Research on Sex and Gender Factors Affecting Women's Health. MUSC is the site of a NIDA-funded SCOR, one of only 11 such Centers in the nation. The SCOR aims to integrate efforts in gender-related research in substance use disorders at MUSC, to build an infrastructure to encourage and support gender-based research growth, to attract early investigators to the area of patient-oriented research, particularly, in women's health issues, and to produce a regional education and training resource for research in women's health.